MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Clinical trials for MALIGNANT PERIPHERAL NERVE SHEATH TUMOR explained in plain language.
Never miss a new study
Get alerted when new MALIGNANT PERIPHERAL NERVE SHEATH TUMOR trials appear
Sign up with your email to follow new studies for MALIGNANT PERIPHERAL NERVE SHEATH TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Matched conditions: MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug hope for rare nerve cancer: tazemetostat under study
Disease control OngoingThis phase 2 trial tests the drug tazemetostat in 10 people with recurrent, treatment-resistant, or metastatic malignant peripheral nerve sheath tumors (MPNST), a rare and aggressive cancer. Participants take tazemetostat pills twice daily for up to 2 years. The main goal is to s…
Matched conditions: MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Phase: PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug combo shows promise for Hard-to-Treat sarcomas
Disease control OngoingThis study tests whether combining two drugs, lenvatinib and pembrolizumab, can safely shrink or control advanced soft tissue sarcomas that have spread or can't be removed by surgery. About 52 adults with specific sarcoma types will receive the combination. The goal is to measure…
Matched conditions: MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Experimental combo aims to boost immune attack on sarcoma before surgery
Disease control OngoingThis early-phase study tests the safety of combining two immunotherapy drugs—nivolumab and BO-112—given before surgery for soft tissue sarcoma that can be removed. About 14 adults with certain sarcoma types will receive these drugs to see if they help the immune system fight the …
Matched conditions: MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Virus and radiation combo takes aim at tough sarcomas
Disease control OngoingThis phase 2 trial tests whether injecting a modified herpes virus (TVEC) directly into tumors, combined with radiation therapy before surgery, can shrink advanced soft tissue sarcomas. The study enrolled 2 adults with specific sarcoma types that could not be removed with clear m…
Matched conditions: MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Phase: PHASE2 • Sponsor: John Rieth • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
10-Year NF1 study aims to unlock secrets of rare genetic disorder
Knowledge-focused OngoingThis natural history study follows 259 children, adolescents, and adults with Neurofibromatosis Type 1 (NF1) for up to 10 years. Researchers will track tumor growth, monitor quality of life, and perform genetic testing to better understand how the disease changes over time. The g…
Matched conditions: MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC